請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/79164
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭守夏 | zh_TW |
dc.contributor.advisor | Shou-Hsia Cheng | en |
dc.contributor.author | 郭蓓蓓 | zh_TW |
dc.contributor.author | Pei-Pei Kuo | en |
dc.date.accessioned | 2021-07-11T15:49:21Z | - |
dc.date.available | 2024-02-28 | - |
dc.date.copyright | 2018-10-09 | - |
dc.date.issued | 2018 | - |
dc.date.submitted | 2002-01-01 | - |
dc.identifier.citation | 中央健康保險署. (2004). 93年降血脂藥物修正. Retrieved from http://www.nhi.gov.tw/02hospital/hospital_file/chap2-3.doc.
中央健康保險署. (2008). 97年降血脂藥物修正. Retrieved from http://www-ws.gov.taipei/001/Upload/public/Attachment/97811401727.doc. 中央健康保險署. (2013a). 全民健康保險藥物給付項目及支付標準共同擬訂會議藥品部分第3次(102年6月)會議紀錄 )降血脂藥物財務推估. 中央健康保險署. (2013b). 健保降低降血脂藥品的用藥門檻,與國際治療標準接軌. Retrieved from http://www.nhi.gov.tw/epaperN/ItemDetail.aspx?DataID=3371&IsWebData=0&ItemTypeID=5&PapersID=293&PicID=. 中央健康保險署. (2014a). 全民健康保險降血脂藥物給付規定表. Retrieved from http://tsoc.org.tw/upload/2014/03/20140308160954.pdf 中央健康保險署. (2014b). 全民健康保險藥物給付項目及支付標準-第六編第八十三條. Retrieved from http://www.nhi.gov.tw/resource/bulletin/4616_%E4%BF%AE%E6%AD%A3%E8%A6%8F%E5%AE%9A.pdf 中華民國血脂及動脈硬化學會 (Producer). (2008). 2008 台灣地區血脂治療共識摘要. 醫學新知. Retrieved from http://www.tsoc.org.tw/upload/journal/2/20081201/1.pdf 汪辰陽. (2016). 臺灣住院診斷關聯群(Tw-DRGs)對多重慢性病患資源耗用及照護結果的影響. 國立臺灣大學健康政策與管理研究所碩士論文. 邱春吉,陳世明,李炳鈺,戴慶玲,江吉文. (2012 ). 高危險群門診病患Statin類藥物治療型態與費用效益評估. 臺灣醫學, 16(1). doi:10.6320/FJM.2012.16(1).01 國民健康署. (2014). 2009-2013 年急性心肌梗塞標準化發生率. Retrieved from http://www.tsim.org.tw/board/276.files/103 09 26%E6%96%B0%E8%81%9E%E7%A8%BF%E9%99%84%E4%BB%B6_%E4%B8%89.pdf 國民健康署(原國民健康局). (2011). 2007年台灣地區高血壓、高血糖、高血脂之追蹤調查研究. Retrieved from https://www.hpa.gov.tw/Pages/ashx/File.ashx?FilePath=~/File/Attach/1243/File_1005.pdf. 萬芳醫院內科部、藥劑部. 降血脂之用藥指導手冊. 衛生福利部. (2018). 106年國人死因統計結果. Retrieved from https://www.mohw.gov.tw/cp-16-41794-1.html 衛生福利部統計處. (2017). 歷年死亡原因. Retrieved from https://www.mohw.gov.tw/dl-18472-6bf0ba7a-a435-47ff-ae4c-03b73ca1ae76.html. Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Buck, G., Pollicino, C., . . . Cholesterol Treatment Trialists, C. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 366(9493), 1267-1278. doi:10.1016/S0140-6736(05)67394-1 Barker-Collo, S., Bennett, D. A., Krishnamurthi, R. V., Parmar, P., Feigin, V. L., Naghavi, M., . . . Group, G. B. D. S. P. E. (2015). Sex Differences in Stroke Incidence, Prevalence, Mortality and Disability-Adjusted Life Years: Results from the Global Burden of Disease Study 2013. Neuroepidemiology, 45(3), 203-214. doi:10.1159/000441103 Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., . . . Stroke Statistics, S. (2017). Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation, 135(10), e146-e603. doi:10.1161/CIR.0000000000000485 Chen, P. S., Cheng, C. L., Kao Yang, Y. H., & Li, Y. H. (2016). Statin Adherence After Ischemic Stroke or Transient Ischemic Attack Is Associated With Clinical Outcome. Circ J, 80(3), 731-737. doi:10.1253/circj.CJ-15-0753 Cholesterol Treatment Trialists, C., Kearney, P. M., Blackwell, L., Collins, R., Keech, A., Simes, J., . . . Baigent, C. (2008). Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 371(9607), 117-125. doi:10.1016/S0140-6736(08)60104-X Cui, Y., Hao, K., Takahashi, J., Miyata, S., Shindo, T., Nishimiya, K., . . . Shimokawa, H. (2017). Age-Specific Trends in the Incidence and In-Hospital Mortality of Acute Myocardial Infarction Over 30 Years in Japan- Report From the Miyagi AMI Registry Study. Circ J, 81(4), 520-528. doi:10.1253/circj.CJ-16-0799 Damiani, G., Federico, B., Anselmi, A., Bianchi, C. B., Silvestrini, G., Iodice, L., . . . Ricciardi, W. (2014). The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis. BMC Health Serv Res, 14, 6. doi:10.1186/1472-6963-14-6 Degano, I. R., Salomaa, V., Veronesi, G., Ferrieres, J., Kirchberger, I., Laks, T., . . . Acute Myocardial Infarction Trends in Europe Study, I. (2015). Twenty-five-year trends in myocardial infarction attack and mortality rates, and case-fatality, in six European populations. Heart, 101(17), 1413-1421. doi:10.1136/heartjnl-2014-307310 Hennessy, D. A., Tanuseputro, P., Tuna, M., Bennett, C., Perez, R., Shields, M., . . . Manuel, D. G. (2016). Population health impact of statin treatment in Canada. Health Rep, 27(1), 20-28. Lee, M., Wu, Y. L., & Ovbiagele, B. (2016). Trends in Incident and Recurrent Rates of First-Ever Ischemic Stroke in Taiwan between 2000 and 2011. J Stroke, 18(1), 60-65. doi:10.5853/jos.2015.01326 Li, Y. C., & Huang, W. L. (2015). Effects of Adherence to Statin Therapy on Health Care Outcomes and Utilizations in Taiwan: A Population-Based Study. Biomed Res Int, 2015, 149573. doi:10.1155/2015/149573 National Cholesterol Education Program Expert Panel on Detection, E., & Treatment of High Blood Cholesterol in, A. (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106(25), 3143-3421. Pandya, A., Sy, S., Cho, S., Weinstein, M. C., & Gaziano, T. A. (2015). Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA, 314(2), 142-150. doi:10.1001/jama.2015.6822 Pencina, M. J., Navar-Boggan, A. M., D'Agostino, R. B., Sr., Williams, K., Neely, B., Sniderman, A. D., & Peterson, E. D. (2014). Application of new cholesterol guidelines to a population-based sample. N Engl J Med, 370(15), 1422-1431. doi:10.1056/NEJMoa1315665 Rosamond, W. D., Chambless, L. E., Heiss, G., Mosley, T. H., Coresh, J., Whitsel, E., . . . Folsom, A. R. (2012). Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008. Circulation, 125(15), 1848-1857. doi:10.1161/CIRCULATIONAHA.111.047480 Rossouw, J. E., Lewis, B., & Rifkind, B. M. (1990). The value of lowering cholesterol after myocardial infarction. N Engl J Med, 323(16), 1112-1119. doi:10.1056/NEJM199010183231606 Simoens, S., & Sinnaeve, P. R. (2014). Patient co-payment and adherence to statins: a review and case studies. Cardiovasc Drugs Ther, 28(1), 99-109. doi:10.1007/s10557-013-6497-2 Stamler, J., Wentworth, D., & Neaton, J. D. (1986). Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 256(20), 2823-2828. Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., . . . American College of Cardiology/American Heart Association Task Force on Practice, G. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 129(25 Suppl 2), S1-45. doi:10.1161/01.cir.0000437738.63853.7a Talwalkar, P. G., Sreenivas, C. G., Gulati, A., & Baxi, H. (2013). Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV. Indian J Endocrinol Metab, 17(4), 628-635. doi:10.4103/2230-8210.113753 Thai, L. P., Moss, J. R., Godman, B., & Vitry, A. I. (2016). Cost driver analysis of statin expenditure on Australia’s Pharmaceutical Benefits Scheme. Expert Review of Pharmacoeconomics & Outcomes Research, 16(3), 419-433. doi:10.1586/14737167.2016.1136790 Vangen-Lonne, A. M., Wilsgaard, T., Johnsen, S. H., Carlsson, M., & Mathiesen, E. B. (2015). Time trends in incidence and case fatality of ischemic stroke: the tromso study 1977-2010. Stroke, 46(5), 1173-1179. doi:10.1161/STROKEAHA.114.008387 Wang, W., & Zhang, B. (2014). Statins for the prevention of stroke: a meta-analysis of randomized controlled trials. PLoS One, 9(3), e92388. doi:10.1371/journal.pone.0092388 Wang, Y., Rudd, A. G., & Wolfe, C. D. (2013). Age and ethnic disparities in incidence of stroke over time: the South London Stroke Register. Stroke, 44(12), 3298-3304. doi:10.1161/STROKEAHA.113.002604 Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., . . . Payne, N. (2007). A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess, 11(14), 1-160, iii-iv. Wilson, P. W., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., Kannel, W. B. (1998). Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation, 97, 1837-1847. Wong, N. D., Wilson, P. F., & Kannel, W. B. (1991). Serum cholesterol as a prognostic factor after myocardial infarction: The framingham study. Annals of Internal Medicine, 115(9), 687-693. doi:10.7326/0003-4819-115-9-687 World Health Organization. (2017). Cardiovascular disease. On World Heart Day WHO calls for accelerated action to prevent the world’s leading global killer. Retrieved from http://www.who.int/cardiovascular_diseases/en/ Yin, W. H., Lu, T. H., Chen, K. C., Cheng, C. F., Lee, J. C., Liang, F. W., . . . Yang, L. T. (2016). The temporal trends of incidence, treatment, and in-hospital mortality of acute myocardial infarction over 15years in a Taiwanese population. Int J Cardiol, 209, 103-113. doi:10.1016/j.ijcard.2016.02.022 | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/79164 | - |
dc.description.abstract | 背景:近年來心血管疾病在各國造成龐大的疾病負擔,其中一個重要的危險因子即為高血脂,迄今已有許多臨床證據顯示降血脂藥物對於疾病初級及次級預防的效益,而國際相關準則也更正治療指引。台灣於2013年8月1日正式修正降血脂藥物的給付規定,放寬對於高危險族群,心血管病史或糖尿病患者的藥物給付的治療血脂起始值。然而,目前國內外尚未有研究針對降血脂藥物的放寬給付政策對健康結果及花費效益之影響做評估。
目的:本研究主要探討台灣於2013年更改給付規定後,對於影響族群糖尿病患者之降血脂藥物的開立、降血脂藥物延伸對於疾病的發生率、醫療花費之影響。 方法:使用全民健康保險全人口資料庫進行分析,選取2010年無心血管疾病史的糖尿病患者作為政策介入組,無心血管疾病史、無糖尿病史的高血壓患者為政策對照組。以2010年8月1日為追蹤起始時間,追蹤至2016年7月31日。採用差異中的差異法,分析政策實施前後,介入組與對照組的降血脂藥物開立趨勢、心血管疾病的發生率、降血脂藥費差異、心血管疾病醫療費用差異。 結果:研究發現在政策實施後,介入及對照組的降血脂藥物開立人數皆上升,介入組上升較為明顯,且差異達統計上顯著,因此政策影響介入組較大。心血管疾病發生率部分,發現介入組的缺血性腦中風發生率於政策實施後第三年趨緩,疾病花費也有趨緩,但未達統計上顯著差異,而藥費相對於對照組則是沒有上升太多,未達統計上顯著差異。 結論:2013年的放寬給付政策讓高風險族群之一的糖尿病患者的開藥人數上升,相對於對照組,藥費沒有明顯的上升,而心血管疾病中的缺血性腦中風發生率及花費漸趨緩但未達統計上顯著差異,建議相關單位再做更長的觀察評估。 | zh_TW |
dc.description.abstract | Background:Recently, cardiovascular diseases (CVD) has been causing heavier disease burdens globally. Dyslipidemia is one crucial risk factor, and many clinical studies have proven the primary and secondary CVD prevention benefits of hypolipidemic drugs. Furthermore, the international guideline was changed to provide new advice for medication. On 2013 August 1st, 2013, Taiwan National Health Insurance (NHI) expanded the hypolipidemic drugs reimbursement criteria for high-risk patients, including patients with CVD history or diabetes. However, few studies have explored the impact and the benefits of expansion drug policy.
Objective:This study aims to evaluate the impact of expanding the hypolipidemic drugs reimbursement criteria on medication usage, CVDs incidence, and the health care expenditure for diabetic patients. Methods:We considered the diabetic patients without CVD history as the intervention group, and the hypertensive patients without CVD and diabetes as the control group. Using August 1, 2013, as the transition point between the pre- and post-policy periods, we performed a difference-in-differences analysis to estimate the effect of hypolipidemic drugs reimbursement criteria expansion. Outcomes included patient numbers under medication, CVDs incidence, and the health care expenditure. The data was extracted from Applied Health Research Data Integration Service from National Health Insurance Administration. Results:After the expansion, patient numbers under medication in the intervention group significantly increased compared to the control group. The rate of increase for the incidence and health care cost of ischaemic stroke slowed after three years of policy implementation, albeit with only marginal significance. The medication expenditure of intervention group did not show any significant increase compared with the control group. Conclusion:The expanded coverage of hypolipidemic drugs significantly increased the number of medications for diabetic patients, but did not increase medication expenditure. The CVDs outcomes, restricted to ischaemic stroke, showed marginally significant decrease in incidence. The policy may have changed high-risk patients’ medication behaviors. However, more data and analysis are needed to evaluate the CVDs outcomes. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T15:49:21Z (GMT). No. of bitstreams: 1 ntu-107-R05848004-1.pdf: 3108180 bytes, checksum: 8c629b0fa2c7823f55bf02ff58fed15c (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii 英文摘要 iii 目錄 v 圖目錄 vii 表目錄 ix 第一章、研究背景 1 第一節、研究動機 1 第二節、研究目的 3 第三節、研究重要性 4 第二章、文獻回顧 5 第一節、心血管疾病現況 5 第二節、心血管疾病與高血脂之相關研究 8 第三節、降血脂治療之發展 10 第四節、台灣降血脂藥物健保給付政策更迭 13 第五節、降血脂藥物使用分析 19 第六節、小結 21 第三章、研究方法 22 第一節、研究設計 22 第二節、研究假說 23 第三節、研究架構 24 第四節、研究材料與對象 26 第五節、研究變項定義 30 第六節、統計分析方法 35 第四章、研究結果 37 第一節、描述性統計 38 第二節、群體層次分析 41 第三節、個體層次之雙變項分析 55 第四節、個體層次之多變項分析 68 第五章、研究討論 73 第一節、研究方法之探討 73 第二節、研究結果之討論 74 第三節、研究假說驗證 82 第四節、研究限制 84 第六章、結論與建議 85 第一節、結論 85 第二節、建議 86 REFERENCE 87 附錄 91 | - |
dc.language.iso | zh_TW | - |
dc.title | 健保放寬降血脂藥物給付範圍對心血管疾病發生率及費用之影響 | zh_TW |
dc.title | The impact on Cardiovascular Diseases Incidence and Costs After the Expansion of Dyslipidemia Drugs in National Health Insurance Coverage | en |
dc.type | Thesis | - |
dc.date.schoolyear | 106-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 賴超倫;李丞華 | zh_TW |
dc.contributor.oralexamcommittee | Chao-Lun Lai;Cheng-Hua Lee | en |
dc.subject.keyword | 降血脂藥物,心血管疾病,高血脂,健保給付政策, | zh_TW |
dc.subject.keyword | Hypolipidemic drugs,Cardiovascular Diseases,Dyslipidemia,Drug policy,Expansion, | en |
dc.relation.page | 96 | - |
dc.identifier.doi | 10.6342/NTU201802235 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2018-07-31 | - |
dc.contributor.author-college | 公共衛生學院 | - |
dc.contributor.author-dept | 健康政策與管理研究所 | - |
dc.date.embargo-lift | 2023-10-09 | - |
顯示於系所單位: | 健康政策與管理研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-2.pdf 目前未授權公開取用 | 3.04 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。